New Biomarker-Guided cocktail aims to wipe out esophageal cancer before surgery
NCT ID NCT06601309
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether a personalized treatment plan based on a biomarker (CPS score) can improve outcomes for people with a certain type of esophageal cancer. Participants will receive a combination of the immunotherapy drug serplulimab, chemotherapy, and possibly radiation before surgery. The main goal is to see how many patients have no cancer left in their removed tissue. The study is currently recruiting 90 adults aged 18-75 with resectable, locally advanced esophageal squamous cell carcinoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Serplulimab (immunotherapy) plus paclitaxel and cisplatin (chemotherapy), with or without radiotherapy
- What this could lead to
- If successful, this approach could increase the chance of eliminating all cancer before surgery, potentially improving long-term outcomes for patients with locally advanced esophageal cancer.
- What could go wrong
- This is an early phase 2 trial with only 90 participants, so results may not apply broadly. The combination of treatments may cause significant side effects, and the benefit over standard care is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads